meta
|
evidence
oncology
Living systematic review and meta-analysis
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
1
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
ipilimumab plus gp100
ipilimumab plus SoC
tremelimumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib
atezolizumab plus SoC
nivolumab based treatment
nivolumab alone
nivolumab followed by ipilimumab
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (2mg/kg)
pembrolizumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
relatlimab plus nivolumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs alkylating agents
vs dacarbazine
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs ipilimumab followed by nivolumab
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs pembrolizumab based treatment
vs pembrolizumab alone
vs Immunostimulant
vs interferon alpha
vs vaccine
vs gp100
vs non active control
vs placebo
All patients
Age < 65y (younger)
Age > 65y
BRAF mutant
BRAF wild type
ECOG ⩾ 1
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
metastasis (brain) NO
metastasis (brain) YES
PD-L1 < 1%
PD-L1 < 5%
PD-L1 > 1%
PD-L1 > 5%
stage III (locally advanced)
stage IV (metastatic)
stage M0
stage M0/M1A/M1B
stage M1A
stage M1B
stage M1C
stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
RFS/DFS
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
SAE (grade 3-4)
SAE leading to death (grade 5)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE grade 3-5 (PE)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Abdominal pain TRAE (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood and lymphatic system disorders TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Chills TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dizziness TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dysgeusia TRAE (grade 3-4)
Dyspepsia TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Ear and labyrinth disorders TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Eye disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Gastritis TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
General disorders and administration site conditions TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hypertension TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Metabolism and nutrition disorders TRAE (grade 3-4)
Musculoskeletal and connective tissue disorders TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nervous system disorders TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritic rash TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Renal and urinary disorders TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Sarcoidosis TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
deaths (OS)
progression or deaths (PFS)
RFS/DFS
mML - NA - all population
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone
1
-
-
-3254 [-4961; -1546]
/10000
15/56 vs. 35/59
versus placebo
nivolumab plus ipilimumab vs. placebo
1
-
-
-5398 [-6977; -3819]
/10000
15/56 vs. 42/52
mML - NA - PDL1 positive
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - PDL1 positive
mML - L1 - all population
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - all population
versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone
2
NaN [NaN; NaN]
/10000
0/0 vs. 0/0
-2409 [-3048; -1769]
/10000
80/409 vs. 158/362
-
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone
1
NaN [NaN; NaN]
/10000
0/0 vs. 0/0
167 [-366; 701]
/10000
45/314 vs. 40/316
-
relatlimab plus nivolumab vs. nivolumab alone
1
-
NaN [NaN; NaN]
/10000
0/0 vs. 0/0
-
mML - L1 - BRAF mutant
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - BRAF mutant
versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone
1
1217 [-2442; 4876]
/10000
12/23 vs. 4/10
-1783 [-5280; 1715]
/10000
12/23 vs. 7/10
-
mML - L1 - BRAF wild
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - BRAF wild
versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone
1
-
-2590 [-4480; -700]
/10000
30/72 vs. 25/37
-
mML - L2 - all population
metastatic/adv melanoma (mML)
mML - 2nd line (L2)
mML - L2 - all population
mML - L2 - BRAF mutant
metastatic/adv melanoma (mML)
mML - 2nd line (L2)
mML - L2 - BRAF mutant
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open